Nasdaq · Healthcare
RxSight, Inc. (RXST)
As-reported financials and recent SEC filings for RxSight, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$134.5M
Net income
$-38.9M
Net margin
-29.0%
Diluted EPS
$-0.95
ROE
-14.1%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M |
| Operating income | $-48.2M | $-36.9M | $-50.1M | $-63.3M | $-52.8M |
| Net income | $-38.9M | $-27.5M | $-48.6M | $-66.8M | $-48.7M |
| Diluted EPS | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-1.78 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-06
View on EDGAR →8-K2026-07-06
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →Largest Healthcare peers
Go deeper on RXST
Search RxSight, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.